Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desloratadine safety in pediatric poor metabolizers
NCT00757562Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Nov 2002
- Primary completion
- Oct 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) and Atopy comparing Desloratadine with Placebo (2 arms). Primary endpoint: Safety and Tolerance at Day 36. Started Nov 2002; status: completed.
02
Drugs
desloratadine
03
Conditions
chronic idiopathic urticaria (CIU)Atopy
Beyond the preview
Go deeper on NCT00757562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00757562.